INO
Inovio Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
3.71 / 10
Netural
Fund flow is strong (7.42/10) with consistent inflows across size segments, though trends are negative. Analyst coverage is thin—one Buy rating from Piper Sandler with zero historical win rate—yielding mixed sentiment. Overall, capital is supportive but analyst confidence is limited.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-14
InstitutionPiper Sandler
Times predicted2
Historical Win Rate0.0%
What is the analyst consensus for INO?
- INO holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.71/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
